FOS and non-small cell lung carcinoma: Furthermore, ERK1/2 agonist induced the downregulation of c-Myc and c-Fos expression, indicating that the ERK1/2 pathway has regulatory effects on the expression of various proliferation genes in NSCLC cells, which is consistent with previous perceptions about genes downstream of the ERK1/2 pathway.